• Brodalumab comes as a solution or a liquid in a prefilled syringe which has to be injected as a subcutaneous injection (under the skin).
• The prefilled syringe should be used only once by injecting all the solution in the syringe. It should be disposed safely in a puncture-resistant container after use.
• Brodalumab can be injected into the thighs, upper arms or stomach except the navel and the area 2 inches around the navel.
• The syringe should not be shaken and care should be taken not to administer it on a psoriatic patch.
• This is followed by injections of 210 mg once for every 2 weeks for a maximum of 16 weeks.
• Allergy to the drug
• Crohn's disease (Brodalumab worsens the disease)
• Chronic or recurrent infections
• Active tuberculosis
• History of mental illness (anxiety or depression) or a mood disorder
• Age less than 18 years old
• The prefilled syringe should be used only once by injecting all the solution in the syringe. It should be disposed safely in a puncture-resistant container after use.
• Brodalumab can be injected into the thighs, upper arms or stomach except the navel and the area 2 inches around the navel.
• The syringe should not be shaken and care should be taken not to administer it on a psoriatic patch.
Dosage & When it is to be taken
• The recommended adult dose is 210 mg injected subcutaneously once a week for 3 consecutive weeks.• This is followed by injections of 210 mg once for every 2 weeks for a maximum of 16 weeks.
When it is not to be taken (Contraindications)
Brodalumab is not recommended in patients with:• Allergy to the drug
• Crohn's disease (Brodalumab worsens the disease)
• Chronic or recurrent infections
• Active tuberculosis
• History of mental illness (anxiety or depression) or a mood disorder
• Age less than 18 years old
